Introduction
Pharmacological modulation of the renin-angiotensin pathway has been shown to be of benefit in a number of cardiovascular diseases. [1] [2] [3] [4] The mainstay of this therapeutic strategy is to block the formation of effector peptide, angiotensin II, by inhibition of angiotensin-converting enzyme (ACE). However, angiotensin II levels have been shown to return to pre-treatment levels following chronic ACE inhibitor therapy, and reductions in blood pressure greater than those observed with ACE inhibitors alone can be obtained by co-administration of angiotensin receptor antagonists with an ACE inhibitor. 5, 6 In addition, increases in plasma angiotensin II following exercise or during ischaemic conditions could not be prevented by an ACE inhibitor. 7, 8 The concept of alternative pathways for angiotensin II formation is supported by a number of in vivo and in vitro experiments. For example, ACE inhibitors alone have been shown to be unable to completely block angiotensin II generation in the human heart and detrusor muscle or block the contractile effect of angiotensin I in isolated blood vessels. [9] [10] [11] [12] These observations suggest the existence of alternative angiotensin II formation pathways which may limit the clinical efficacy of ACE inhibitor therapy.
Alternative angiotensin II generating enzymes
A number of enzymes for which angiotensin I may act as a substrate have been identified. These include tryptensin, cathepsin G, tonin, kallikrein, neutralendopeptidase and chymase. [13] [14] [15] [16] [17] [18] The capacity to generate angiotensin II via an ACE-independent mechanism has been demonstrated in the human myocardium, coronary arteries, internal mammary arteries, saphenous veins, radial arteries and gastroepiploic arteries. 11, 12, [19] [20] [21] [22] 23 The enzyme can be inhibited by the broad spectrum serine protease inhibitors soyabean trypsin inhibitor, chymostatin and phenylmethylsulfonyl fluoride, but not by other protease inhibitors such as EDTA, pepstatin and aprotinin. 24 In a similar fashion to chymotrypsin, chymase hydrolyses peptide bonds at the COOH-termini of hydrophobic aromatic residues. The degree of selectivity over which amino acids are hydrolysed is a function of the extended substrate binding site of the chymase molecule. Thus, human chymase can form angiotensin II by cleavage of the Phe 8 -His 9 bond of the precursor molecule, but it is unable to inactivate angiotensin II since its does not cleave the Tyr 4 -Ile 5 bond in angiotensin II. It is also inactive against substance P, bradykinin, vasoactive intestinal peptide, lutenizing hormone-releasing hormone, somatostatin and alpha-melanocyte-stimulating hormone. 24 In contrast, rat chymase-1, as well as forming angiotensin II from angiotensin I, will also form inactive fragments from angiotensin I and inactivate angiotensin II. Human chymase has been located in the interstitium of the heart, in mast cells, mesenchymal interstitial cells and in endothelial cells. High levels of chymase activity are present in the human uterus, oesophagus, stomach and skin, while moderate levels can be found in tissue from the lung, colon, tonsils, adenoids, renal cortex as well as the left and right ventricles. 25 There are additional enzymes present in mast cells that can generate angiotensin II. Cathepsin G, found in leukocytes as well as mast cells cleaves the same bond in the angiotensin molecule as ACE and chymase and subsequently generates angiotensin II.
14 Another enzyme present in mast cells is the metalloprotease, carboxypeptidase A enzyme. This enzyme cleaves the His 9 -Leu 10 bond in angiotensin I and as a result generates the fragment angiotensin [1] [2] [3] [4] [5] [6] [7] [8] [9] , which although capable of inhibiting ACE, has no known intrinsic contractile activity. 26 The human heart has been shown to possess carboxypeptidase A activity, generation of angiotensin [1] [2] [3] [4] [5] [6] [7] [8] [9] by this enzyme is sufficient to block cardiac ACE. 27 It is undetermined if human blood vessels also exhibit cardoxypeptidase A activity, or if endogenous local ACE activity in the vessel wall is regulated by the synthesis of angiotensin [1] [2] [3] [4] [5] [6] [7] [8] [9] . Other angiotensin fragments may be generated by the action of neutral endopeptidase 24.11 and propyl-endopeptidase 24.26. 28 Both of these enzymes are capable of forming angiotensin 1-7 from angiotensin I. It has been shown that angiotensin [1] [2] [3] [4] [5] [6] [7] possesses the ability to stimulate the release of vasodilator prostanoids and nitric oxide, as well as inhibiting proliferation of vascular smooth muscle cells in balloon injured carotid arteries and rat aorta. [29] [30] [31] Angiotensin II may also be generated via the action of tonin. Tonin, a kallikrenin-like protease has the ability to form angiotensin II from angiotensin I as well as directly from the synthetic renin substrate and from human angiotensinogen. 32, 33 Tonin is normally inactivated in plasma by the endogenous inhibitor alpha 1 -macroglobulin, however, it has recently been shown that even when bound to alpha 1 -macroglobulin, tonin can still generate angiotensin II, which is resistant to ACE inhibition. 34 
Chymase activity and localisation in human blood vessels
It has been shown in a number of human blood vessels that angiotensin I has a similar contractile effect as angiotensin II. In the saphenous vein, IMA, coronary artery, gasteroepiploic artery, and radial artery the contractions observed to angiotensin I persist in the presence of an ACE inhibitor. 11, 12, 20, 35 Incubation of these vessels with the chymase inhibitors soyabean trypsin inhibitor (SBTI) or chymostatin, also fails to inhibit the response to angiotensin I. Dual inhibition of both enzymes is required before any significant inhibitory effect is observed. This has lead to the suggestion that both ACE and chymase have the capacity to generate angiotensin II in the vessel wall, but that the substrate, angiotensin I may be shunted between the enzymes when one or the other has been inhibited. 11, 12 This mechanism may explain why plasma angiotensin II concentrations remain elevated during long term ACE inhibition.
ACE has been demonstrated to be present principally on the vascular endothelial cells of the lumen and vasa vasorum and to a lesser extent in the medial smooth muscle cells. In contrast, chymase has been shown to be present in adventitial mast cells. 11 Despite the different locations of each of these, they both may have the capacity to contribute towards pathological changes within the vessel wall. It has also been shown that in isolated human coronary arteries the angiotensin II synthesised by the action of chymase is rapidly bound to AT 1 receptors. 36 The supply of blood to the vessel wall from the adventitial surface has been shown to be of importance. 37, 38 A number of different animal models of atherosclerosis rely on rendering the vessel wall hypoxic via the occlusion of the vasa vasorum, which results in the initiation of medial necrosis, intimal proliferation and the formation of hyperplastic lesions. 38, 39 Contraction of vasa vasorum by locally formed angiotensin II in the adventitia may initiate pathological changes in the vessel wall. In diseased coronary arteries, exhibiting early and intermediate atherosclerotic lesions, ACE was detected largely in regions of fat laden macrophages and in association with T-lymphocytes. In very diseased lesions, ACE and angiotensin II were localised to endothelial cells lining the micro vessels impregnating the plaque. 40 It has been suggested that angiotensin II formed due to the presence of ACE in areas of inflammation, may contribute to the pathophysiology of coronary artery disease. In addition, mast cells have been shown to accumulate at the site of atherosclerotic lesions in human blood vessels. 41 Mast cell degranulation and activation is evident at the site of advanced lesions in which fissuring, haemorrhage and thrombus formation is evident. Up to 95% of mast cells present within these regions contained both tryptase and chymase.
Role of chymase in disease
There are conflicting reports as to the relative contributions of ACE and chymase in angiotensin II formation in the human heart. 18, 42 In vitro studies have shown chymase to be responsible for up to 80% of cardiac angiotensin II formation. In contrast, in vivo experiments have shown ACE to be the predominant angiotensin II forming enzyme. 43 Data from vascular tissues have shown that human arteries and veins possess ACE activity to varying degrees, 44 and that chymase or chymase-like enzymes, as well as ACE, are responsible for the conversion of angiotensin I into the active peptide. 11, 12, 20, 35 Human atherosclerotic lesions contain many chymase containing mast cells, whose activity and number increase with the severity of the lesion. 45 It is thought that exocytosed heparin-bound chymase released by mast cells may then participate in the early and late development of atherosclerotic lesions. In addition, mast cells may also play a role in the conversion of macrophages into cholesterol loaded foam cells. Lesion stability may also be affected by mast cells due to their ability to degrade apolipoproteins A and B of HDL and LDL respectively. 45 Chymase activity and mRNA expression is increased following balloon injury to dog carotid artery and in atherosclerotic monkey coronary arteries. 46, 47 The subsequent neointimal formation following balloon injury to dog carotid arteries can be inhibited by tranilast, a compound that stabilises mast cells. 46 These findings are of interest in light of the failure of ACE inhibitors to prevent restenosis following percutaneous transluminal coronary angioplasty (PTCA) in humans. 48 Experimental data from rats had suggested that ACE inhibitors would be of benefit following PTCA. However, it is now known that the rat forms angiotensin II almost exclusively via ACE, with little contribution from enzymes such as chymase.
There is also evidence that other angiotensin II forming enzymes are active in vivo. Exerciseinduced angiotensin II release in healthy volunteers can be inhibited by the serine protease inhibitor nafamostat. 8 This drug is also beneficial in patients with peripheral vascular disease. 7 It was originally thought that nafamostat could block the effect of chymase, however, it is now claimed that this inhibitor has no activity against chymase or ACE. Thus the effect of nafamostat may be attributable to its effect on nafamostat-sensitive serine protease(s) such as kallilerin and cathepsin G.
Pharmacological regulation of angiotensin II generation
Inhibition of ACE has a number of addition pharmacological consequences. ACE also breaks down the endothelium-dependent vasodilator bradykinin. Inhibition of ACE can thus prolong the effect of bradykinin, and its subsequent effect on the endothelium. Indeed, it has been shown that ACE inhibitors do improve endothelial function. 49 However, the link between ACE inhibitors, bradykinin and improvements in endothelial function has been questioned. 50 It is known that some ACE inhibitors have an antioxidant effect, which is independent of their effect on angiotensin II, 51, 52 and would promote the action of nitric oxide and improve endothelial function. However, angiotensin II can itself cause oxidant stress. 53 Superoxide levels are increased in angiotensin II treated rats, an effect that correlated with an increase in NADH oxidase activity, increased blood pressure and abnormal endothelial function. 50 Inhibition of ACE blocks these effects, indicating that ACE inhibitors may also achieve an anti-oxidant effect via inhibition of angiotensin II.
However, it is unknown if inhibition of chymase or stabilisation of mast cells can also produce a similar reduction in superoxide generation. Since increases in oxidant stress are believed to activate a wide variety in intra-cellular signalling pathways, which may initiate atherogenesis, the pharmacological inhibiton of angiotensin II formation would be preferable compared to receptor blockade of AT 1 receptors. However, this needs to be weighed-up against the role of the multiple enzyme system that appear to be capable of generating angiotensin II, and the subsequent difficulty in achieving adequate inhibition of angiotensin forming enzymes.
